Clear cell renal cell carcinoma (ccRCC) is the predominant subtype of kidney cancer and remains notoriously refractory to traditional therapeutic approaches, particularly radiotherapy and cytokine-based treatments. Since the early 2000s, several agents targeting angiogenesis and signal transduction—sunitinib, temsirolimus, pazopanib—have provided measurable clinical benefit in randomized trials. However, the efficacy of these treatments remains limited by the frequent emergence of acquired resistance, which justifies the search for new strategies. Two signaling pathways are dysregulated in this disease: the PI3K/Akt pathway, abnormally activated in many high-grade, advanced-stage tumors and associated with a poor prognosis, and the Src kinase, an effector downstream of the EGF receptor, involved in tumor invasion and identified as a common node of multiple resistance pathways.
Building on this observation, the authors evaluated two inhibitors already in phase II clinical trials across various cancers: GDC-0941 (pictilisib), a selective inhibitor of all class I PI3K isoforms, and saracatinib (AZD0530), a dual-specificity inhibitor of Src and Abl kinases. Individually, both compounds display good oral anticancer activity in preclinical models, but responses obtained with GDC-0941 alone are often short-lived, with disease progression frequently occurring within less than a year—a limitation attributed to the concomitant activation of other oncogenic pathways. The hypothesis tested was therefore that combined inhibition of both kinases could overcome this resistance. The compounds were administered alone or in combination on ccRCC cell lines, as well as in murine models and patient-derived xenograft (PDX) models. The work also employed three-dimensional culture, which more faithfully reproduces tumor organization.
The results establish that simultaneous inhibition of PI3K and Src exerts a synergistic effect: the combination curbs the growth and invasion of renal carcinoma cells and induces their death, beyond what each agent achieves on its own. This convergence of effects on proliferation, invasiveness, and cell survival provides a consistent preclinical demonstration across the different models used. The authors conclude that combining these two anticancer agents constitutes a rational strategy to improve the management of kidney cancer, within a framework of synthetic lethality between the two targeted pathways.